Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

© 2019 MORU. Photographer: Prayoon Yuentrakul
Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site

Coordinated by the Menzies School of Health Research (Menzies, Darwin, Australia), the Mahidol Oxford Tropical Medicine Research Unit (MORU, Bangkok, Thailand) and the Eijkman Institute of Molecular Biology (Jakarta, Indonesia), the IMPROV (Improving the Radical Cure of Vivax Malaria) trial involved > 2,000 patients in Ethiopia, Afghanistan, Indonesia and Vietnam and tested the treatment effectiveness of a high-dose 7 day course of primaquine.

Its findings challenge the standard treatment regimen that has been widely used for the last 60 years.

The WHO recommends that patients with P. vivax malaria are treated with antimalarial drugs to clear the parasites in the blood followed by a 14-day course of primaquine to kill the liver hypnozoites and prevent recurrent bouts of malaria.

Associate Senior Clinical Research Fellow Dr Bob Taylor, MORU, says adherence to the standard 14-day regimen is poor.

“Primaquine is the only widely available drug that kills the P. vivax hypnozoites in the liver, but patients often fail to complete the treatment once they feel better. We found that the 7-day high-dose course of primaquine was as effective as the recommended 14-day treatment,” Dr Taylor said.

P. vivax malaria is a major cause of illness in Asia, Oceania, the Horn of Africa, and the Americas. The P. vivax parasites has dormant forms in the liver called hypnozoites, that wake up weeks to months later causing relapses - multiple episodes of malaria that lead to repeated illness and time out of work and school.

Senior Researcher Dr Kamala Thriemer (Menzies) says a shorter treatment prevents multiple episodes of malaria that lead to ill health particularly in young children and pregnant women.

“The shorter, 7 day primaquine regimen worked very well, with very few people having another episode of malaria within 12 months. Although some patients had minor side effects, the drug was generally well tolerated,” Dr Thriemer said.

The study’s principal investigator Prof Ric Price (University of Oxford) said: “Vivax malaria is becoming the predominant cause of malaria in the Asia Pacific. A short course primaquine regimen is much easier to administer and patients are more likely to complete treatment.

“If used widely, this new regimen could help reduce and accelerate the elimination of vivax malaria from the region,” said Prof Price.

Reference

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Taylor et al, The Lancet.

Funders

This research was funded by the: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).

Similar stories

Outbreak: fighting coronavirus

NDM

In a new Oxford Science Blog, Charvy Narain (Communications & Public Engagement Manager, Radcliffe Department of Medicine) talks to some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak.

Researchers find new cells that repair tissue

NDM

Researchers from Nuffield Department of Medicine have discovered that a newly discovered group of cells can help repair tissues in the body.

Rapidly spreading multidrug-resistant parasites render frontline malaria drug ineffective in southeast Asia

NDM

A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.

Award-winning citizen science project tackling TB gets millionth classification

NDM

An award-winning Oxford-based international project to tackle antibiotic resistance has achieved its one millionth classification.

UK-led study marks shift towards genetic era in tackling TB

NDM

In a landmark study that may herald a quicker, more tailored treatment for the millions of people around the world living with tuberculosis (TB), UK researchers have shown how our understanding of TB’s genetic code is now so detailed that we can now predict which commonly used anti-TB drugs are best for treating a patient’s infection and which are not.

MAIT cells protect against pulmonary Legionella longbeachae infection

NDM

New paper published in Nature Communications from researchers in Respiratory Medicine Unit, NDM Experimental Medicine'